These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 27151693)

  • 1. Histopathological changes induced by selective inactivation of menin on the thyroid gland in RET÷PTC3 and E7 transgenic mice. A study of 77 cases.
    Căpraru OM; Berger N; Gadot N; Decaussin-Petrucci M; Zhang C; Borda A; Szilágyi T; Borson-Chazot F; Selmi-Ruby S
    Rom J Morphol Embryol; 2016; 57(1):91-8. PubMed ID: 27151693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papilloma virus 16 E7 oncogene does not cooperate with RET/PTC 3 oncogene in the neoplastic transformation of thyroid cells in transgenic mice.
    Portella G; Borselli C; Santoro M; Gerbasio D; D'Armiento MR; Dumont JE; Ledent C; Rothstein JL; Vecchio G; Fusco A
    Oncol Res; 2001; 12(8):347-54. PubMed ID: 11589306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice.
    Jin L; Burniat A; Dumont JE; Miot F; Corvilain B; Franc B
    Br J Cancer; 2008 Dec; 99(11):1874-83. PubMed ID: 18985036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of connexin32 deletion on E7 or RET/PTC3 oncogene-driven growth and neoplastic transformation of the thyroid gland.
    Prost G; Bernier-Valentin F; Croset M; Rousset B
    Endocr Relat Cancer; 2009 Sep; 16(3):873-84. PubMed ID: 19509066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
    Powell DJ; Russell J; Nibu K; Li G; Rhee E; Liao M; Goldstein M; Keane WM; Santoro M; Fusco A; Rothstein JL
    Cancer Res; 1998 Dec; 58(23):5523-8. PubMed ID: 9850089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers.
    Burniat A; Jin L; Detours V; Driessens N; Goffard JC; Santoro M; Rothstein J; Dumont JE; Miot F; Corvilain B
    Endocrinology; 2008 Oct; 149(10):5107-17. PubMed ID: 18583418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High iodine concentration attenuates RET/PTC3 oncogene activation in thyroid follicular cells.
    Fiore AP; Fuziwara CS; Kimura ET
    Thyroid; 2009 Nov; 19(11):1249-56. PubMed ID: 19725779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells.
    Shinohara S; Rothstein JL
    Oncogene; 2004 Sep; 23(45):7571-9. PubMed ID: 15326486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/- mice.
    Powell DJ; Russell JP; Li G; Kuo BA; Fidanza V; Huebner K; Rothstein JL
    Oncogene; 2001 May; 20(25):3235-46. PubMed ID: 11423973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells.
    Miyagi E; Braga-Basaria M; Hardy E; Vasko V; Burman KD; Jhiang S; Saji M; Ringel MD
    Mol Carcinog; 2004 Oct; 41(2):98-107. PubMed ID: 15378648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid-stimulating hormone promotes growth of thyroid carcinomas in transgenic mice with targeted expression of the ret/PTC1 oncogene.
    Sagartz JE; Jhiang SM; Tong Q; Capen CC
    Lab Invest; 1997 Mar; 76(3):307-18. PubMed ID: 9121114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia.
    Bellelli R; Vitagliano D; Federico G; Marotta P; Tamburrino A; Salerno P; Paciello O; Papparella S; Knauf JA; Fagin JA; Refetoff S; Troncone G; Santoro M
    Mol Cell Endocrinol; 2018 Jan; 460():24-35. PubMed ID: 28652169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma.
    Basolo F; Giannini R; Monaco C; Melillo RM; Carlomagno F; Pancrazi M; Salvatore G; Chiappetta G; Pacini F; Elisei R; Miccoli P; Pinchera A; Fusco A; Santoro M
    Am J Pathol; 2002 Jan; 160(1):247-54. PubMed ID: 11786418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
    Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
    J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
    Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
    Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice.
    Cho JY; Sagartz JE; Capen CC; Mazzaferri EL; Jhiang SM
    Oncogene; 1999 Jun; 18(24):3659-65. PubMed ID: 10380889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
    Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
    Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
    Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
    Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.